Danaher Stock: It Beat Earnings and RAISED Guidance — So Why Did DHR Fall? (Our Call: HOLD)

Danaher Corporation (DHR) Q2 2026 — Danaher (DHR), the wide-moat life-sciences and diagnostics compounder, reported a solid Q2 2026: adjusted EPS of $1.94 beat the ~$1.84 estimate (+8% YoY) on revenue of $6.27B (+5.5%, core +3.0%). GAAP EPS jumped 60% to $1.23 (flattered by a prior-year impairment). Management RAISED full-year 2026 adjusted EPS guidance to $8.45–$8.60 (from $8.35–$8.55), helped by closing the ~$9.9B Masimo acquisition early (June 10). The key tell: bioprocessing orders grew mid-teens — the destocking that broke the stock is ending. Yet DHR (~$201, down ~1.3% on the print) slipped, because core growth is still just 3% and the deal added ~$8B of debt. After a de-rating from a $242 high to a $162 low, our owner-earnings DCF lands fair value near $205 — essentially the price. Our call: HOLD, 3/5 — a wonderful compounder, finally at a fair price. Danaher is one of the great compounding machines in the market — a ~$142B maker of the picks-and-shovels of life science and diagnostics (about 75% recurring revenue), run by CEO Rainer Blair on the legendary Danaher Business System. Q2 2026 was a solid quarter: adjusted EPS of $1.94 beat the ~$1.84 estimate (+8% YoY), revenue rose 5.5% to $6.27B (core +3.0%), and GAAP EPS jumped 60% to $1.23 (flattered by a prior-year impairment). For the win, management RAISED full-year adjusted EPS guidance to $8.45–$8.60 (from $8.35–$8.55), helped by closing the ~$9.9B Masimo patient-monitoring acquisition early on June 10. The most important tell wasn't on the P&L: bioprocessing orders grew mid-teens, the clearest sign yet that the two-year destocking that broke this stock is ending, with Life Sciences posting its best quarter in years. So why did the stock slip? Because the recovery is still a promise — core growth is only 3% (Q3 guided +2–3%), the Masimo deal added ~$8B of debt (total ~$26.6B), and it dilutes margins near-term. After a brutal de-rating from a $242 high to a $162 low and back to ~$201, our owner-earnings DCF (base ~$5.5B FCF; steady 6%→4% = $134–$189, compounder 10%→5.5% = $182–$277) lands fair value near $205 — essentially today's price. A wonderful business, finally fair, but not yet a bargain. Our call: HOLD, 3/5. We're a touch more cautious than the Street's bullish ~$242 (Buy), and we'd add aggressively on the dips this volatile stock keeps handing out (mid-$160s in May, ~$181 in June). Watch bioprocessing orders. Not financial advice. THE CALL: HOLD (3/5, A WONDERFUL COMPOUNDER, FINALLY AT A FAIR PRICE — A BEAT-AND-RAISE WITH NO MARGIN OF SAFETY YET) — base-case value ~$205 vs ~$201 today. What to watch: evidence the bioprocessing recovery is real in the numbers, not just orders — two or three quarters of accelerating core revenue growth as bioprocessing converts and Masimo contributes — which would justify the Street's higher target and prompt an upgrade; the risk to respect is a stalled recovery with core growth stuck near 3% while ~$8B of Masimo debt and integration weigh on returns, which at a fair-not-cheap price would leave the stock treading water Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.